Free Trial

Virpax Pharmaceuticals Q4 2022 Earnings Report

Virpax Pharmaceuticals logo
$0.29 -0.01 (-3.42%)
As of 01/21/2025 04:00 PM Eastern

Virpax Pharmaceuticals EPS Results

Actual EPS
-$2.60
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Virpax Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Virpax Pharmaceuticals Announcement Details

Quarter
Q4 2022
Time
N/A

Conference Call Resources

Virpax Pharmaceuticals Earnings Headlines

Virpax Pharmaceuticals Inc Ordinary Shares
Please take this warning seriously...
I’m here to issue a stark warning to you about an unexpected $2 trillion shock that could impact every trader in the country – in the next 30 days. In fact, I believe it could begin as soon as January 29th… Meaning you don’t have much time to prepare.
Virpax Updates Executive Agreements for Legal Compliance
See More Virpax Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Virpax Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Virpax Pharmaceuticals and other key companies, straight to your email.

About Virpax Pharmaceuticals

Virpax Pharmaceuticals (NASDAQ:VRPX), a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain. The company's preclinical stage product candidates also comprise AnQlar, an anti-viral barrier to prevent or reduce the risk or the intensity of viral infections in humans, including influenza and SARS-CoV-2; and NobrXiol, an investigational formulation to be delivered via the nasal route to enhance cannabidiol transport to the brain. Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania.

View Virpax Pharmaceuticals Profile

More Earnings Resources from MarketBeat